	US 12,448,420 B2
	Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease
Dong Ho Song, Seongnam-si (KR)
Assigned to GBIOLOGICS INC., Seongnam-si (KR)
Appl. No. 17/763,902
Filed by GBIOLOGICS INC., Seongnam-si (KR)
PCT Filed Nov. 11, 2020, PCT No. PCT/KR2020/015782 § 371(c)(1), (2) Date Mar. 25, 2022, PCT Pub. No. WO2021/096217, PCT Pub. Date May 20, 2021.
Claims priority of application No. 10-2019-0143752 (KR), filed on Nov. 11, 2019; and application No. 10-2020-0149295 (KR), filed on Nov. 10, 2020.
Prior Publication US 2022/0372088 A1, Nov. 24, 2022
Int. Cl. A61K 38/17 (2006.01); A61P 19/02 (2006.01); A61P 19/10 (2006.01); C07K 14/47 (2006.01); C12N 15/66 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 38/17 (2013.01); A61K 38/1732 (2013.01); A61P 19/02 (2018.01); A61P 19/10 (2018.01); C07K 14/4726 (2013.01); C12N 15/66 (2013.01)]

4 Claims

1. A method for treatment of a bone disease, comprising:

administering to an individual in need thereof a pharmaceutically effective amount of a recombinant stabilized galectin 9 protein having the amino acid sequence set forth as SEQ ID NO: 1,

wherein the bone disease is rheumatoid arthritis.